ロード中...
Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
Hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory syndrome driven by overactive T cells and macrophages that abundantly secrete numerous pro-inflammatory cytokines, including interferon (IFN)-gamma, interleukin (IL)-1-beta, IL-2, IL-6, IL-10, IL-18, and tumor necrosis factor (TNF)...
保存先:
| 出版年: | Front Immunol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7923355/ https://ncbi.nlm.nih.gov/pubmed/33664745 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.614704 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|